Fibrinolysis and the plasma carboxypeptidase

Current Opinion in Hematology

Volumn 5, Issue 5, 1998, Pages 309-313

  Nesheim, Michael ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE; ENZYME PRECURSOR; FIBRIN; LYSINE; THROMBIN; THROMBOMODULIN;

BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; ENZYME BLOOD LEVEL; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031696875     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199809000-00001     Document Type: Review

References (40)

1. Davie EW, Fujikawa K, Kisiel W: The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991, 30:10363-10370.
2. Collen D, Lijnen HR: Molecular and cellular basis of fibrinolysis. In Hematology: Basic Principles and Practice. Edited by Hoffman R, Benz E, Shattil S, Furie B, Cohen H. New York: Churchill Livingstone; 1991:1232-1242.
3. Esmon CT: Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993, 70:29-35.
4. Horrevoets AJG, Smilde A, de Vries C, Pannekoek H: The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during the in vitro fibrinolysis. J Biol Chem 1994, 269:12639-12644.
5. Nesheim ME, Fredenburgh JC, Larsen GR: The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant dFEIX with intact fibrin. J Biol Chem 1990, 265:21541-21548.
6. Miles LA, Plow EF: Plasminogen receptors: ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988, 2:61-71.
7. Sjoholm I: Studies on the conformational changes of plasminogen induced during activation to plasmin and by 6-aminohexanoic acid. Eur J Biochem 1973, 39:471-479.
8. Lijnen HR, Collen D: Alpha 2-antiplasmin. In Proteinase Inhibitors. Edited by Barrett AJ, Salvesen G. New York: Elsevier Science Publishers BV; 1986:457-476.
9. de Vries C, Veerman H, Nesheim ME, Pannekoek H: Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants. Thromb Haemost 1991, 65:280-285.
10. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF: Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991, 30:1682-1691.
11. Lenich C, Pannell R, Gurewich V: The effect of the carboxy-terminal lysine of urokinase on the catalysis of plasminogen activation. Thromb Res 1991, 64:69-80.
12. Fleury V, Angles-Cano E: Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991, 30:7630-7638.
13. Pannell R, Black J, Gurewich V: Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988, 81:853-859.
14. Hendriks D, Wang W, Scharpe S, Lommaert MP, van Sande M: Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990, 1034:86-92.
15. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D: Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991, 269:21833-21838.
16. Tan AK, Eaton DL: Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995, 34:5811-5816.
17. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 1995, 270:14477-14484.
18. Broze GJ Jr, Higuchi DA: Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996, 88:3815-3823.
19. von dem Borne PA, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN: • Thrombin mediated activation of factor XI in a TAFI (thrombin activatable fibrinolysis inhibitor) dependent inhibition of fibrinolysis. J Clin Invest 1997, 99:2323-2327. Demonstrates that the intrinsic pathway mediates inhibition of fibrinolysis and that the process is dependent on TAFI.
20. Bajzar L, Morser J, Nesheim M: TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996, 271:16603-16608.
21. Redlitz A, Tan AK, Eaton DL, Plow EF: Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995, 96:2534-2538.
22. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L: • Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997, 78:386-391. A recent review of the properties and role of the plasma carboxypeptidase.
23. Wang W, Hendriks DF, Scharpe SS: Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994, 269:15937-15944.
24. Bajzar L, Nesheim M: The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem 1993, 268:8608-8616.
25. Bertina RM, van Tilburg NH, de Fouw NJ, Haverkate F: Thrombin, a link between coagulation activation and fibrinolysis. Ann N Y Acad Sci 1993, 239-248.
26. Bajzar L, Nesheim ME, Tracy PB: The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996, 88:2093-2100.
27. Boffa MB, Wang W, Bajzar L, Nesheim ME: Plasma and recombinant • thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998, 273:2127-2135. Provides a comparison of plasma and recombinant TAFI and characterizes the intrinsic instability of TAFIa.
28. Vanhoof G, Wauters J, Schatteman K, Hendriks D, Goossens F, Bossuyt P, Scharpe S: The gene for human carboxypeptidase U (CPU): a proposed novel regulator of plasminogen activation-maps to 13q14.11. Genomics 1996, 38:454-455.
29. Sakharov DV, Plow EF, Rijken DC: On the mechanism of the antifibrinolytic • activity of plasma carboxypeptidase B. J Biol Chem 1997, 272:14477-14482. Analyzes the mechanism of inhibition of fibrinolysis by the plasma carboxypeptidase. The authors also show inhibition of fibrinolysis even at high levels of tissue plasminogen activator, such as those achieved in therapeutic thrombolysis.
30. Wang W, Boffa MB, Walker J, Nesheim ME: A study of the mechanism of inhibition of tPA-mediated fibrinolysis by activated TAFI [abstract]. Fibrinolysis 1996, 10 (abstract 278):82.
31. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME: A study of the • mechanism of inhibition of fibrinolysis by activated TAFI. J Biol Chem 1988, in press. Provides a quantitative analysis of the mechanism of inhibition of fibrinolysis by TAFIa.
32. Valnickova Z, Thogersen IB, Christensen S, Chu CT, Pizzo SV, Enghild JJ: Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha 2 macroglobulin and pregnancy zone protein. J Biol Chem 1996, 271:12937-12943.
33. Bajzar L, Nesheim ME, Morser J, Tracy PB: Both cellular and soluble forms • of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998, 273:2792-2798. Endothelial cell thrombomodulin promotes TAFI activation and suppression of fibrinolysis.
34. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF: Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996, 93:1328-1330.
35. Minnema MC, Friedrich PW, Levi M, von dem Borne PAK, Mosnier LQ, • Meijers JCM, Biemond BJ, Hack CE, Bouma BN, ten Cate H: Enhancement of jugular vein thrombolysis by neutralization of factor XI: in vivo evidence for a role of factor XI as an antifibrinolytic factor. J Clin Invest 1998, 101:1-5. This article shows factor XI-dependent inhibition of fibrinolysis in vivo, and that inhibition of factor XI enhances endogenous lysis of jugular vein clots in rabbits.
36. Mann KG: Thrombosis: Theoretical considerations. Am J Clin Nutr 1997, 65(suppl):1657S-1664S.
37. Dahlback B: Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Lab Clin Med 1995, 125:566-571.
38. Kalafatis M, Mann KG: Factor V Leiden and thrombophilia. Arterioscler Thromb 1997, 17:620-627.
39. van't Veer C, Kalafatis M, Bertina RM, Simioni P, Mann KG: Increased • tissue factor-initiated prothrombin activation as a result of the Arg 506 → Gln mutation in factor V Leiden. J Biol Chem 1997, 272:20721-20729. Provides a definitive analysis of the kinetic defect in factor V Leiden.
40. Bajzar L, Kalafatis M, Simioni P, Tracy PB: An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996, 271:22949-22952